Advertisement

Gerard (Rod) Riedel has been named vice president, regulatory affairs and program management, at Wellesley biotech NormOxys Inc.

In his new role, Riedel will be responsible for leading the company’s drug development and working with national health authorities and regulatory agencies. Specifically, he will help advance NormOxys’ lead drug candidate, OXY111A, which is being tested in clinical studies to treat cancer and cardiovascular diseases.

SOURCE

Advertisement
Advertisement